AbbVie (NYSE:ABBV) recently announced the availability of its drug SKYRIZI® in Canada for treating adults with ulcerative ...
Aldeyra's reproxalap faced an FDA setback but showed positive trial results, leading to a resubmitted NDA. Click here to find ...
Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) shot up 0.6% on Wednesday after Wells Fargo & Company raised their price target on the stock from $210.00 to $240.00. Wells Fargo & Company ...
The European makers of Ozempic for diabetes and Cetaphil for dry skin said they would feel an impact from President Donald ...
Denali Therapeutics’ amyotrophic lateral sclerosis (ALS) drug has racked up another clinical miss this year, leaving the ...
Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...
Zacks Investment Research on MSN23h
Here's How to Play AbbVie Stock as it Enters the Obesity SpaceAbbVie ABBV announced that it is in-licensing rights to develop phase I candidate, GUB014295, a long-acting amylin analog for ...
AbbVie Inc. ( NYSE: ABBV) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET Scott T. Reents - Executive Vice President and Chief Financial Officer Jeffrey R. Stewart - Executive ...
AbbVie, Thermo Fisher Scientific, Danaher, Vertex Pharmaceuticals, and Illumina are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks represent ...
NewsNation on MSN14h
AbbVie enters into almost $2B contract with Gubra for obsesity drugBloomberg reports the obesity drug market is expected to reach as much as $130 billion in annual sales by 2030.
Class will soon be in session at the Allergan Aesthetics headquarters. The AbbVie brand plans to open doors at its ...
In this week’s InnovationRx newsletter, tariffs could hit medical devices, a gene therapy company that helps blind kids see ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback